ARAF is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRAF is altered in 61.96% of pilocytic astrocytoma patients [2].

BRAF is an inclusion eligibility criterion in 2 clinical trials for pilocytic astrocytoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and pilocytic astrocytoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

Cobimetinib, vemurafenib, dabrafenib, and trametinib have evidence of efficacy in patients with BRAF mutation in pilocytic astrocytoma [3].

CRKL is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR1 is altered in 6.75% of pilocytic astrocytoma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR3 is altered in 1.23% of pilocytic astrocytoma patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KIAA1549 is altered in 53.15% of pilocytic astrocytoma patients [2].

KIAA1549 is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains KIAA1549 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KRAS is altered in 3.68% of pilocytic astrocytoma patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K1 is altered in 0.61% of pilocytic astrocytoma patients [2].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K2 is altered in 2.08% of pilocytic astrocytoma patients [2].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K4 is altered in 0.61% of pilocytic astrocytoma patients [2].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP3K1 is altered in 2.45% of pilocytic astrocytoma patients [2].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYB is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MYB status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYBL1 is altered in 0.73% of pilocytic astrocytoma patients [2].

MYBL1 is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MYBL1 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NF1 is altered in 9.2% of pilocytic astrocytoma patients [2].

NF1 is an inclusion eligibility criterion in 2 clinical trials for pilocytic astrocytoma, of which 2 are open and 0 are closed. Of the trials that contain NF1 status and pilocytic astrocytoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

NF2 is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PTPN1 is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains PTPN1 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAF1 is altered in 1.84% of pilocytic astrocytoma patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SOS1 is altered in 0.85% of pilocytic astrocytoma patients [2].

SOS1 is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SRC is an inclusion eligibility criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].